Autologous macrophage therapy increases transplant-free survival in cirrhosis: Long-term follow-up of a phase 2 clinical trial - PubMed
4 hours ago
- #autologous macrophage therapy
- #regenerative medicine
- #cirrhosis treatment
- Autologous macrophage therapy demonstrated safety and potential efficacy in phase 1/2 MATCH01 trial for cirrhosis.
- Long-term follow-up showed macrophage-treated patients had significantly lower risk of death or transplant (30.8%) vs standard care (58.3%).
- Macrophage-treated patients gained an additional 252 days of restricted mean survival time over up to 4 years.
- No evidence of increased serious adverse events attributable to cell therapy was found.
- Results support advancement of macrophage-based regenerative strategies as promising therapeutic for end-stage liver disease.